On May 1, 2017, the U.S. Court of Appeals for the Federal
Circuit issued an opinion in Helsinn Healthcare S.A. v. Teva
Pharmaceuticals USA, Inc. that considered the America Invents
Act ("AIA")'s changes to the on-sale bar rule of 35
U.S.C. § 1021. Specifically, the Court addressed
the extent to which an alleged sale must be made "public"
in order to trigger application of the on-sale bar post-AIA. Based
on the particular facts of this case, the Court found that a
purchase and sale agreement that was publicly disclosed satisfied
the post-AIA on-sale bar, even though the public disclosure did not
include all of the details about the claimed invention.
Before Congress enacted the AIA, § 102 barred the
patentability of an invention that was "patented or described
in a printed publication in this or a foreign country or in public
use or on sale in this country, more than one year prior to the
date of application for patent."2 The AIA amended
§ 102, so that it now bars the